UACT sends letter to Tufts President, Chairman of Trustees, asking questions about R&D cost study

On November 24, 2014. the Union for Affordable Cancer Treatment (UACT) sent a letter to Anthony P. Monaco, Office of the President, Tufts University, with copies to Michael Baenen, the Tufts Chief of Staff, and Peter Dolan, Chairman of the Board of Trustees for Tufts University, regarding the Tufts University press conference to announce an estimate of $2.6 billion as the R&D costs for new drugs. Continue Reading

The Winning Bet

Leading up to the release of Professor Joe DiMasi’s latest study of the cost of drug development, KEI offered $50 to the individual who could most accurately predict the new cost for drug R&D.

We received 26 guesses, ranging from $1.157 billion to $5 billion.

Joel Lexchin’s estimate ($2.47 billion) was the closest to DiMasi’s number ($2.558 billion). It was also the 5th largest estimate.

A complete list of submissions is below.

Name & Guess
Charles Clift – 1.157 billion
Nicole H – 1.2 billion
Ronald Rader – 1.55 billion
Wouter Deelder – 1.655 billion
Continue Reading